Latest Communications News

NOVONIX ended the September quarter with US$33.652 million in cash after burning US$9.765 million in operations and repaying US$7 million of Yorkville debt. Its amended PowerCo framework also removes previous volume, pricing and delivery commitments, leaving customer qualification and future funding as the company’s central tests.

Epiminder has enrolled its 100th patient in the DETECT US epilepsy study ahead of schedule, while maintaining A$65.1 million in cash and no borrowings. The company says those reserves can fund clinical development and commercialisation work well into 2028.

Ambertech has reported a $2.251 million FY26 statutory loss after taking about $3.2 million in goodwill, inventory and restructuring charges. Cash flow and inventory improved, but the ASX-listed technology distributor will not pay a final dividend as it turns FY27 into an execution test.

Swift TV expanded its contracted footprint and qualified pipeline in the September quarter, but ended with $1.047 million in cash and only 0.9 quarters of funding at the reported burn rate. The company is relying on customer receipts, an expected $1.5 million R&D incentive and lending arrangements as commercial deployments accelerate.

Glencore delivered a stronger third quarter across several key commodities and expects 2026 Marketing Adjusted EBIT to exceed $5 billion. Copper production improved on a like-for-like basis, while ferrochrome output climbed as South African smelters restarted.

Vectus Biosystems has secured FDA acceptance of a pre-IND Type B meeting for VB0004, a key regulatory step for its idiopathic pulmonary fibrosis programme. The biotech ended September with $410,000 in cash and reported estimated funding for just 1.33 quarters of operations.

4DS Memory has completed its acquisition of Jenesys and appointed founder Jaspal Sarai as CEO, combining autonomous-systems software with its ReRAM technology. The company has A$6.6 million in quarter-end cash plus a further A$2 million placement, but has yet to secure a binding customer agreement.

BSA Limited (ASX:BSA) suffered a steep first-quarter revenue decline after the nbn contract expired, with underlying EBITDA falling to a $0.6 million loss. The company is now relying on pipeline conversion and the proposed Eonetics acquisition to rebuild its earnings base.

PYC Therapeutics has moved all four RNA drug programs towards their next development milestones, while reporting $655 million in cash and treasury investments at 30 September. The company’s standalone cash balance covers just 1.13 quarters, making its liquid investment portfolio central to the stated funding runway through 2030.

Li-S Energy has delivered its lithium-sulfur Power Cells to a US Army research centre and completed a near two-hour endurance flight with its Pegasus drone. The milestones advance its defence and aerospace commercialisation pipeline, but neither has yet produced a procurement order or confirmed revenue.

Control Bionics has begun converting its expanded product and regulatory pipeline into revenue, while a completed $9.75 million capital raising gives the company a larger cash buffer. The next test is whether partner-led sales and NeuroStrip trial conversions can reduce its cash burn as planned.

MGX Resources has moved from planning to construction at its Central Tanami gold project while completing its final Koolan Island iron ore shipments. The company ended the September quarter with $408.7 million in cash and investments, but key value milestones now depend on drilling, approvals and the Crestlink sale settling.